 |
|
The Prevalence of Metoclopramide-Induced Tardive Dyskinesia and Acute Extrapyramidal Movement Disorders
Linda Ganzini, MD;
Daniel E. Casey, MD;
William F. Hoffman, PhD, MD;
Anthony L. McCall, MD, PhD
Arch Intern Med. 1993;153(12):1469-1475.
Abstract
Background
Metoclopramide hydrochloride, a neuroleptic dopamine receptor antagonist used to treat gastric ailments, is reported to cause extrapyramidal movement disorders. The goals of this study were (1) to determine the prevalence and severity of tardive dyskinesia and acute extrapyramidal movement syndromes including akathisia, acute dystonia, and drug-induced parkinsonism in metoclopramide-treated patients and (2) to compare the prevalence and severity of tardive dyskinesia in metoclopramide-treated diabetics and nondiabetics.
Methods
From a list of metoclopramide-treated patients received from the Portland (Ore) Veterans Affairs Medical Center pharmacy, 53 patients met inclusion criteria and 51 (96%) agreed to participate. Controls consisted of a convenience sample drawn from the Portland Veterans Affairs Medical Center Outpatient Clinic who were matched to subjects on age (±10 years), gender, and presence or absence of diabetes. Of 61 potential controls contacted, 51 (84%) agreed to participate. Metoclopramide-treated subjects and controls were seen by a rater who was "blind" to all diagnoses and treatments. The rater performed a standardized examination used to elicit signs and symptoms of tardive dyskinesia and acute extrapyramidal movement syndromes.
Results
The relative risk for tardive dyskinesia was 1.67 (95% confidence interval, 0.93 to 2.97), and the relative risk for drug-induced parkinsonism was 4.0 (95% confidence interval, 1.5 to 10.5). Metoclopramide-treated patients had significantly greater severity of tardive dyskinesia, drug-induced parkinsonism, and subjective akathisia than controls. Use of metoclopramide was associated with impairment in ambulation and increased use of benzodiazepines. Metoclopramidetreated diabetics had significantly greater severity of tardive dyskinesia than metoclopramide-treated nondiabetics.
Conclusions
Metoclopramide use is associated with a significantly increased prevalence and severity of several extrapyramidal movement disorders.
(Arch Intern Med. 1993;153:1469-1475)
Author Affiliations
From the Portland Veterans Affairs Medical Center and the Oregon Health Sciences University, Portland.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Current issues on safety of prokinetics in critically ill patients with feed intolerance
Nguyen and Yi Mei
Therapeutic Advances in Drug Safety 2011;2:197-204.
ABSTRACT
Drug induced parkinsonism: a common cause of parkinsonism in older people
Thanvi and Treadwell
Postgrad. Med. J. 2009;85:322-326.
ABSTRACT
| FULL TEXT
Comparison of metoclopramide oral tablets and solution in treatment of dysmotility-like dyspepsia
Banani et al.
Am J Health Syst Pharm 2008;65:1057-1061.
ABSTRACT
| FULL TEXT
Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia
Kenney et al.
J Clin Pharmacol 2008;48:379-384.
FULL TEXT
Intravenous administration of metoclopramide by 2 min bolus vs 15 min infusion: does it affect the improvement of headache while reducing the side effects?
Parlak et al.
Postgrad. Med. J. 2007;83:664-668.
ABSTRACT
| FULL TEXT
Rate of metoclopramide infusion affects the severity and incidence of akathisia
Parlak et al.
Emerg. Med. J. 2005;22:621-624.
ABSTRACT
| FULL TEXT
Chronic Metoclopramide Therapy for Diabetic Gastroparesis
Lata and Pigarelli
The Annals of Pharmacotherapy 2003;37:122-126.
ABSTRACT
| FULL TEXT
Acute Dystonia Due to Metoclopramide: Increased Risk in AIDS
van der Kleij et al.
Arch Intern Med 2002;162:358-359.
FULL TEXT
Treating Constipation in the Patient With Diabetes
Haines
The Diabetes Educator 1995;21:223-232.
HOW COMMONLY DOES METOCLOPRAMIDE CAUSE MOVEMENT DISORDERS?
JWatch General 1993;1993:4-4.
FULL TEXT
|
